Keyphrases
Graft-versus-host Disease (GvHD)
100%
Sickle Cell Disease
63%
Hematopoietic Cell Transplantation
59%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
55%
Pediatric Patients
47%
Reduced-intensity Conditioning
46%
Pediatric
42%
Hematopoietic Stem Cell Transplantation
37%
Severe Combined Immunodeficiency
36%
Stem Cell Transplantation
34%
Unrelated Donor
33%
Hematopoietic Stem Cell Transplant
32%
Marrow Transplantation
29%
Busulfan
28%
Chronic Myeloid Leukemia
25%
Transplantation
24%
Fludarabine
22%
Primary Immune Deficiency
19%
Myelodysplastic Syndrome
19%
Infection Diagnosis
19%
Remestemcel-L
19%
Older Adults
17%
Malignant Disorders
16%
Pediatric Leukemia
16%
Late Effects
15%
Event-free Survival
15%
Engraftment
15%
Area under the Curve
15%
Donor chimerism
15%
Allogeneic
14%
Graft Failure
14%
Hematological Malignancies
14%
Improved Outcomes
13%
Graft Rejection
13%
Thalassemia
13%
Overall Survival
13%
Alemtuzumab
13%
Infection Prophylaxis
12%
Transplantation Therapy
12%
Cord Blood Transplantation
12%
Human Mesenchymal Stem Cells (hMSCs)
12%
Gastrointestinal Graft-versus-host Disease
12%
Late Acute
12%
Next-generation Sequencing
12%
Umbilical Cord Blood
12%
Conditioning Regimen
12%
High Risk
11%
Tyrosine Kinase Inhibitor
11%
Myeloablative Conditioning
11%
Acute Myeloid Leukemia
11%
Medicine and Dentistry
Hematopoietic Cell
80%
Pediatrics
68%
Cell Transplantation
66%
Graft Versus Host Reaction
50%
Hematopoietic Stem Cell Transplantation
42%
Sickle-Cell Disease
38%
Diseases
36%
Chronic Myelogenous Leukemia
31%
Chronic Graft Versus Host Disease
31%
Acute Graft Versus Host Disease
30%
Infection
25%
Reduced Intensity Conditioning
23%
Immune Deficiency
20%
Severe Combined Immunodeficiency
19%
Pediatrics Patient
17%
Graft Failure
17%
Late Effect
15%
Stem Cell Therapy
15%
Cord Blood
15%
Fludarabine
14%
Overall Survival
13%
Tyrosine-Kinase Inhibitor
13%
Myelodysplastic Syndrome
13%
Childhood Cancer
12%
Mesenchymal Stem Cell
12%
Next Generation Sequencing
12%
Conditioning
11%
Stem Cell Transplant
11%
Graft Rejection
11%
Event Free Survival
11%
Newborn Screening
10%
Disease
10%
Thalassemia
10%
Bone Marrow Transplantation
10%
Allogeneic Hematopoietic Stem Cell Transplantation
10%
Acute Myeloid Leukemia
10%
Clinical Trial
9%
Neoplasm
9%
Prospective Study
8%
Hematologic Malignancy
7%
Alternative Donor
7%
Bloodstream Infection
7%
Hazard Ratio
7%
Leukemia
7%
Immunosuppressive Treatment
7%
Hemoglobinopathy
7%
Myeloablative Conditioning
7%
Cell Therapy
6%
Biological Marker
6%
T Cell
6%
Immunology and Microbiology
Hematopoietic Cell
90%
Cell Transplantation
78%
Conditioning
53%
Hematopoietic Stem Cell Transplantation
48%
Graft-Versus-Host Disease
40%
Acute Graft Versus Host Disease
35%
Sickle Cell
31%
Severe Combined Immunodeficiency
30%
T Cell
26%
Chronic Graft Versus Host Disease
26%
Engraftment
26%
Cord Blood Stem Cell Transplantation
19%
Remestemcel L
19%
Overall Survival
16%
Mesenchymal Stem Cell
16%
Allogeneic Hematopoietic Stem Cell Transplantation
14%
Umbilical Cord Blood
14%
Myeloid
13%
CD34
13%
Immunodeficiency
13%
Granulocyte Colony-Stimulating Factor
12%
Stem Cell Transplantation
12%
Next Generation Sequencing
12%
Alemtuzumab
12%
Neutrophil
12%
Allograft
11%
Event Free Survival
11%
Newborn Screening
10%
Blood Plasma
10%
CD19
8%
T Cell Receptor
8%
Cyclophosphamide
8%
Immune Reconstitution
8%
Primary Immunodeficiency
8%
Disease Free Survival
7%
Pharmacokinetics
7%
Stem Cell Transplant
7%
Lymphocytopenia
7%
Arm
7%
Immunosuppression
7%
Phytohaemagglutinin
6%
Mevalonic aciduria
6%
Autologous Stem Cell Transplantation
6%
Umbilical Cord
6%
Clinical Immunology
6%
Wiskott-Aldrich Syndrome
6%
X-Linked Agammaglobulinemia
6%
Mesenchymal Stem Cell Transplantation
6%
Blood Flow
6%
Chronic Granulomatous Disease
6%